Company: CRL
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001100682-25-000011
Chunk: 172

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-02-19
Form: 10-K
Item: Item 8
Chunk 172
---
ATORIES INTERNATIONAL, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

12. EQUITY AND NONCONTROLLING INTERESTS

Earnings Per ShareThe following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share:Fiscal Year202420232022(in thousands)Numerator:Net income$25,291 $480,370 $492,608 Less: Net income attributable to noncontrolling interests3,088 5,746 6,382 Net income attributable to Charles River Laboratories International Inc.$22,203 $474,624 $486,226 Calculation of net income per share attributable to Charles River Laboratories International Inc. common shareholdersNet income attributable to Charles River Laboratories International Inc.$22,203 $474,624 $486,226 Less: Incremental dividends attributed to noncontrolling interest holders (1)11,906 — — Net income available to Charles River Laboratories International Inc. common shareholders$10,297 $474,624 $486,226 Denominator:Weighted-average shares outstanding - Basic51,380 51,227 50,812 Effect of dilutive securities:Stock options, restricted stock units and performance share units248 224 489 Weighted-average shares outstanding - Diluted51,628 51,451 51,301 Anti-dilutive common stock equivalents (2)530 652 560 (1) Represents incremental declared and undeclared dividends attributable to Noveprim noncontrolling interest holders who are entitled to preferential dividends for fiscal year 2024.(2) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.Treasury SharesOn August 2, 2024, the Company’s Board of Directors approved a stock repurchase authorization of $1.0 billion. This authorization fully replaces a prior stock repurchase authorization of $1.3 billion that had $129.1 million remaining when it was terminated. In fiscal year 2024, the Company repurchased 0.5 million shares of common stock for $100.7 million under the new stock repurchase program.As of December 28, 2024, the Company had $899.3 million remaining on the current authorized stock repurchase program. As of December 30, 2023, the Company had